RU2018124603A - Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 - Google Patents
Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 Download PDFInfo
- Publication number
- RU2018124603A RU2018124603A RU2018124603A RU2018124603A RU2018124603A RU 2018124603 A RU2018124603 A RU 2018124603A RU 2018124603 A RU2018124603 A RU 2018124603A RU 2018124603 A RU2018124603 A RU 2018124603A RU 2018124603 A RU2018124603 A RU 2018124603A
- Authority
- RU
- Russia
- Prior art keywords
- ccl20
- patient
- level
- disease
- paragraphs
- Prior art date
Links
- 102100036848 C-C motif chemokine 20 Human genes 0.000 title claims 33
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 title claims 33
- 108010065637 Interleukin-23 Proteins 0.000 title claims 28
- 102000013264 Interleukin-23 Human genes 0.000 title claims 28
- 239000005557 antagonist Substances 0.000 title claims 12
- 238000000034 method Methods 0.000 claims 30
- 229940124829 interleukin-23 Drugs 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 12
- 230000001404 mediated effect Effects 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 6
- 102100024484 Codanin-1 Human genes 0.000 claims 4
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 claims 4
- 230000001900 immune effect Effects 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000013691 Interleukin-17 Human genes 0.000 claims 2
- 108050003558 Interleukin-17 Proteins 0.000 claims 2
- 102100030703 Interleukin-22 Human genes 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100026887 Beta-defensin 103 Human genes 0.000 claims 1
- 102100026886 Beta-defensin 104 Human genes 0.000 claims 1
- 102100038326 Beta-defensin 4A Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 102100023795 Elafin Human genes 0.000 claims 1
- 108010015972 Elafin Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims 1
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims 1
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 claims 1
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 claims 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 1
- 102100036679 Interleukin-26 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 claims 1
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 101000912227 Pan troglodytes Beta-defensin 104A Proteins 0.000 claims 1
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 102100029812 Protein S100-A12 Human genes 0.000 claims 1
- 102100032446 Protein S100-A7 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims 1
- 108700016890 S100A12 Proteins 0.000 claims 1
- 101150097337 S100A12 gene Proteins 0.000 claims 1
- 102100036383 Serpin B3 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960002874 briakinumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229950010864 guselkumab Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 108010074109 interleukin-22 Proteins 0.000 claims 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 229950007943 risankizumab Drugs 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271156P | 2015-12-22 | 2015-12-22 | |
| US62/271,156 | 2015-12-22 | ||
| PCT/US2016/067120 WO2017112536A1 (en) | 2015-12-22 | 2016-12-16 | Ccl20 as a predictor of clinical response to il23-antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018124603A true RU2018124603A (ru) | 2020-01-24 |
| RU2018124603A3 RU2018124603A3 (enExample) | 2020-04-06 |
Family
ID=59091179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018124603A RU2018124603A (ru) | 2015-12-22 | 2016-12-16 | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11220541B2 (enExample) |
| EP (1) | EP3393515A4 (enExample) |
| JP (2) | JP2019508370A (enExample) |
| KR (1) | KR20180096633A (enExample) |
| CN (1) | CN108472367A (enExample) |
| AU (1) | AU2016379157A1 (enExample) |
| BR (1) | BR112018012626A2 (enExample) |
| CA (1) | CA3007098A1 (enExample) |
| IL (1) | IL259704A (enExample) |
| MX (1) | MX2018007589A (enExample) |
| RU (1) | RU2018124603A (enExample) |
| WO (1) | WO2017112536A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| FI13575Y1 (fi) * | 2018-09-24 | 2024-03-26 | Janssen Biotech Inc | IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| TW202102538A (zh) * | 2019-03-26 | 2021-01-16 | 美商阿斯特捷利康合作創業有限責任公司 | 適合il23拮抗劑療法的患者群體 |
| KR20230165746A (ko) | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| CN113092652B (zh) * | 2021-03-19 | 2022-09-30 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
| CN114113630B (zh) * | 2021-11-24 | 2023-07-28 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DK0937259T3 (da) | 1996-11-01 | 2005-01-31 | Magne K Fagerhol | Fremgangsmåde til ekstraktion af proteiner |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| RU2006135119A (ru) | 2004-03-05 | 2008-04-10 | Аркемикс Корп. (Us) | Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| EA013506B1 (ru) | 2005-08-25 | 2010-06-30 | Эли Лилли Энд Компани | Антитело к il-23 и его применение |
| EP2354160A1 (en) | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
| EP1954719A2 (en) | 2005-12-02 | 2008-08-13 | Genentech Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| AU2006330411B2 (en) | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| MX2009009079A (es) | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US7833721B2 (en) | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| CN102202655B (zh) | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2414393A1 (en) | 2009-04-01 | 2012-02-08 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| CA2766157A1 (en) | 2009-06-25 | 2010-12-29 | Hua Gong | Methods for diagnosing irritable bowel syndrome |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PH12012501016A1 (en) | 2009-11-25 | 2013-01-14 | Prometheus Laboratories Inc | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| IN2012DN06720A (enExample) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| US9732387B2 (en) | 2012-04-03 | 2017-08-15 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and Crohn's disease |
-
2016
- 2016-12-16 JP JP2018532465A patent/JP2019508370A/ja active Pending
- 2016-12-16 MX MX2018007589A patent/MX2018007589A/es unknown
- 2016-12-16 BR BR112018012626A patent/BR112018012626A2/pt not_active Application Discontinuation
- 2016-12-16 WO PCT/US2016/067120 patent/WO2017112536A1/en not_active Ceased
- 2016-12-16 US US16/063,803 patent/US11220541B2/en active Active
- 2016-12-16 EP EP16879907.0A patent/EP3393515A4/en not_active Withdrawn
- 2016-12-16 CA CA3007098A patent/CA3007098A1/en not_active Abandoned
- 2016-12-16 CN CN201680075323.4A patent/CN108472367A/zh active Pending
- 2016-12-16 RU RU2018124603A patent/RU2018124603A/ru not_active Application Discontinuation
- 2016-12-16 KR KR1020187017346A patent/KR20180096633A/ko not_active Withdrawn
- 2016-12-16 AU AU2016379157A patent/AU2016379157A1/en not_active Abandoned
-
2018
- 2018-05-30 IL IL259704A patent/IL259704A/en unknown
-
2021
- 2021-10-22 JP JP2021172872A patent/JP2022031643A/ja active Pending
- 2021-11-29 US US17/536,663 patent/US20220144935A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018012626A2 (pt) | 2018-12-04 |
| US20200262907A1 (en) | 2020-08-20 |
| CA3007098A1 (en) | 2017-06-29 |
| US20220144935A1 (en) | 2022-05-12 |
| US11220541B2 (en) | 2022-01-11 |
| JP2022031643A (ja) | 2022-02-22 |
| CN108472367A (zh) | 2018-08-31 |
| WO2017112536A1 (en) | 2017-06-29 |
| JP2019508370A (ja) | 2019-03-28 |
| IL259704A (en) | 2018-07-31 |
| MX2018007589A (es) | 2018-11-09 |
| EP3393515A4 (en) | 2019-08-14 |
| KR20180096633A (ko) | 2018-08-29 |
| RU2018124603A3 (enExample) | 2020-04-06 |
| AU2016379157A1 (en) | 2018-06-21 |
| EP3393515A1 (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018113694A (ru) | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| JP2018535394A5 (enExample) | ||
| JP6563976B2 (ja) | 可溶性ヒトｓｔ−２抗体およびアッセイ法 | |
| JP2019508370A5 (enExample) | ||
| DK2564202T3 (en) | A method for detecting anti-drug antibodies | |
| RU2658601C2 (ru) | Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба | |
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| AU2018299068A1 (en) | Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine | |
| CN104870012A (zh) | 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 | |
| JP5792637B2 (ja) | 関節炎状態を特徴づけるための組成物および方法 | |
| CN116660522A (zh) | 定量il-33的方法和组合物 | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| CN106526196B (zh) | Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用 | |
| US10697961B2 (en) | Methods for predicting post-operative recurrence of Crohn's disease | |
| US11644473B2 (en) | Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients | |
| CN116179497A (zh) | 抗人il-17a蛋白的单克隆抗体及其应用 | |
| AU2016269576B2 (en) | Soluble human ST-2 antibodies and assays | |
| AU2013204182B2 (en) | Soluble human ST-2 antibodies and assays | |
| CN116286667A (zh) | 抗人il-17a蛋白的单克隆抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211110 |